Nifty
Sensex
:
:
22904.45
75364.69
-345.65 (-1.49%)
-930.67 (-1.22%)

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 533573 | NSE: APLLTD

894.95
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  892.00
  •  916.75
  •  875.90
  •  888.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  135156
  •  1207.86
  •  1303.90
  •  725.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 17,472.50
  • 28.89
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 18,338.50
  • 1.24%
  • 3.48

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.61%
  • 0.17%
  • 7.26%
  • FII
  • DII
  • Others
  • 4.17%
  • 15.66%
  • 3.13%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.72
  • 6.22
  • 5.49

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.97
  • -5.14
  • 1.30

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.10
  • -5.77
  • 5.74

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.72
  • 27.30
  • 32.78

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.82
  • 3.50
  • 3.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.76
  • 16.53
  • 18.68

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
31.33
32.75
42.45
53.64
P/E Ratio
34.73
33.23
25.63
20.29
Revenue
6229
6708
7507
8350
EBITDA
933
1085
1340
1626
Net Income
616
645
835
1054
ROA
9.8
10.7
12.8
14.3
P/B Ratio
4.44
4.07
3.64
3.21
ROE
13.4
12.86
15.07
17.19
FCFF
429.98
475.63
646.25
750.43
FCFF Yield
1.96
2.16
2.94
3.41

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
1,692.75
1,630.57
3.81%
1,647.98
1,594.93
3.33%
1,561.73
1,486.15
5.09%
1,516.98
1,406.45
7.86%
Expenses
1,432.52
1,364.21
5.01%
1,408.71
1,386.69
1.59%
1,324.90
1,287.45
2.91%
1,256.92
1,194.23
5.25%
EBITDA
260.23
266.36
-2.30%
239.27
208.24
14.90%
236.83
198.70
19.19%
260.06
212.22
22.54%
EBIDTM
15.37%
16.34%
14.52%
13.06%
15.16%
13.37%
17.14%
15.09%
Other Income
9.50
2.89
228.72%
16.74
10.15
64.93%
2.10
11.66
-81.99%
3.59
0.89
303.37%
Interest
22.26
15.17
46.74%
18.81
15.69
19.89%
13.18
14.39
-8.41%
10.94
14.37
-23.87%
Depreciation
70.04
69.45
0.85%
70.51
67.56
4.37%
69.04
66.18
4.32%
69.48
74.12
-6.26%
PBT
177.43
184.63
-3.90%
179.56
135.14
32.87%
156.71
129.79
20.74%
183.23
124.62
47.03%
Tax
40.09
4.13
870.70%
27.28
-1.93
-
22.49
9.16
145.52%
4.63
-36.43
-
PAT
137.34
180.50
-23.91%
152.28
137.07
11.10%
134.22
120.63
11.27%
178.60
161.05
10.90%
PATM
8.11%
11.07%
9.24%
8.59%
8.59%
8.12%
11.77%
11.45%
EPS
7.04
9.18
-23.31%
7.81
6.95
12.37%
6.85
6.14
11.56%
9.07
7.76
16.88%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
6,419.44
6,228.62
5,652.62
5,305.78
5,393.14
4,605.76
3,934.69
3,130.81
3,134.61
3,165.99
2,056.13
Net Sales Growth
4.93%
10.19%
6.54%
-1.62%
17.10%
17.06%
25.68%
-0.12%
-0.99%
53.98%
 
Cost Of Goods Sold
1,642.12
1,715.08
1,708.82
1,446.43
1,257.35
1,039.38
992.71
886.19
887.57
823.95
639.85
Gross Profit
4,777.32
4,513.54
3,943.80
3,859.35
4,135.79
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
1,416.28
GP Margin
74.42%
72.46%
69.77%
72.74%
76.69%
77.43%
74.77%
71.69%
71.68%
73.97%
68.88%
Total Expenditure
5,423.05
5,296.00
4,944.56
4,431.64
3,913.05
3,391.69
3,078.87
2,515.55
2,519.90
2,160.88
1,660.92
Power & Fuel Cost
-
173.37
151.54
120.84
118.72
102.40
88.86
70.35
64.20
58.89
43.31
% Of Sales
-
2.78%
2.68%
2.28%
2.20%
2.22%
2.26%
2.25%
2.05%
1.86%
2.11%
Employee Cost
-
1,446.29
1,169.13
1,133.00
1,051.17
906.44
746.69
622.81
558.83
472.85
306.76
% Of Sales
-
23.22%
20.68%
21.35%
19.49%
19.68%
18.98%
19.89%
17.83%
14.94%
14.92%
Manufacturing Exp.
-
387.71
409.37
379.15
372.18
368.41
269.25
244.53
289.79
271.51
263.38
% Of Sales
-
6.22%
7.24%
7.15%
6.90%
8.00%
6.84%
7.81%
9.24%
8.58%
12.81%
General & Admin Exp.
-
525.84
492.64
413.90
391.24
339.82
340.56
283.43
299.79
233.28
145.68
% Of Sales
-
8.44%
8.72%
7.80%
7.25%
7.38%
8.66%
9.05%
9.56%
7.37%
7.09%
Selling & Distn. Exp.
-
996.88
952.30
890.38
687.41
531.19
590.28
380.21
393.14
274.14
244.69
% Of Sales
-
16.00%
16.85%
16.78%
12.75%
11.53%
15.00%
12.14%
12.54%
8.66%
11.90%
Miscellaneous Exp.
-
50.83
60.76
47.94
34.98
104.05
50.52
28.03
26.58
26.26
244.69
% Of Sales
-
0.82%
1.07%
0.90%
0.65%
2.26%
1.28%
0.90%
0.85%
0.83%
0.84%
EBITDA
996.39
932.62
708.06
874.14
1,480.09
1,214.07
855.82
615.26
614.71
1,005.11
395.21
EBITDA Margin
15.52%
14.97%
12.53%
16.48%
27.44%
26.36%
21.75%
19.65%
19.61%
31.75%
19.22%
Other Income
31.93
29.04
3.04
50.49
87.48
13.88
27.14
34.87
2.58
8.83
12.09
Interest
65.19
56.19
50.17
17.73
16.02
27.16
18.41
3.40
5.23
5.43
3.81
Depreciation
279.07
272.67
275.43
286.78
183.47
157.32
115.23
105.46
82.97
72.21
44.41
PBT
696.93
632.80
385.50
620.12
1,368.08
1,043.47
749.32
541.27
529.09
936.30
359.07
Tax
94.49
16.01
12.60
104.46
253.32
199.18
156.75
120.36
122.19
216.12
76.35
Tax Rate
13.56%
2.53%
3.27%
16.85%
18.52%
19.92%
20.92%
22.24%
23.09%
23.08%
21.26%
PAT
602.44
615.82
341.99
520.94
1,114.76
828.76
593.65
420.72
406.99
720.18
282.72
PAT before Minority Interest
603.60
615.82
341.99
520.94
1,114.76
800.64
592.57
420.91
406.90
720.18
282.72
Minority Interest
1.16
0.00
0.00
0.00
0.00
28.12
1.08
-0.19
0.09
0.00
0.00
PAT Margin
9.38%
9.89%
6.05%
9.82%
20.67%
17.99%
15.09%
13.44%
12.98%
22.75%
13.75%
PAT Growth
0.53%
80.07%
-34.35%
-53.27%
34.51%
39.60%
41.10%
3.37%
-43.49%
154.73%
 
EPS
30.64
31.32
17.40
26.50
56.70
42.15
30.20
21.40
20.70
36.63
14.38

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
4,818.20
4,370.47
5,237.54
5,066.98
3,219.42
2,718.83
2,220.14
1,902.33
1,597.36
884.64
Share Capital
39.31
39.31
39.31
39.31
37.70
37.70
37.70
37.70
37.70
37.70
Total Reserves
4,778.89
4,331.16
5,198.23
5,027.67
3,181.72
2,681.13
2,182.44
1,864.63
1,559.66
846.94
Non-Current Liabilities
2.75
52.42
162.07
361.16
1,046.98
570.06
576.20
94.15
84.02
72.44
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
18.80
Unsecured Loans
0.00
0.00
0.00
199.89
886.99
499.30
500.00
0.00
0.00
0.00
Long Term Provisions
109.51
106.20
95.82
85.52
74.51
52.03
40.76
57.22
28.23
9.36
Current Liabilities
1,520.28
1,640.80
1,830.59
1,533.26
1,751.61
1,663.65
1,267.18
813.96
944.19
684.09
Trade Payables
735.64
679.81
706.39
668.78
625.93
644.34
759.32
500.73
565.65
324.94
Other Current Liabilities
223.66
251.19
516.51
557.92
226.98
380.19
142.89
81.28
51.80
44.56
Short Term Borrowings
430.45
635.87
430.00
0.02
860.50
429.13
207.78
88.51
113.71
219.70
Short Term Provisions
130.53
73.93
177.69
306.54
38.20
209.99
157.19
143.44
213.03
94.88
Total Liabilities
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17
Net Block
2,546.71
2,398.45
1,797.85
1,788.42
1,551.84
1,158.45
993.38
799.40
708.09
546.87
Gross Block
3,875.21
3,467.50
2,840.33
2,545.39
2,132.41
1,522.57
1,242.47
950.09
1,093.63
861.06
Accumulated Depreciation
1,328.50
1,069.05
1,042.48
756.97
580.57
364.12
249.09
150.69
385.54
314.19
Non Current Assets
3,197.39
3,149.80
4,255.37
4,056.96
3,526.30
2,820.02
2,116.31
1,316.80
917.30
750.43
Capital Work in Progress
524.36
601.28
2,304.24
2,182.53
1,846.18
1,551.23
1,010.15
396.28
92.52
83.14
Non Current Investment
93.02
96.33
118.40
49.31
17.62
48.76
41.64
49.88
53.43
2.26
Long Term Loans & Adv.
33.30
53.74
34.88
36.70
110.66
61.58
71.14
71.24
29.96
118.15
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
33.30
0.00
Current Assets
3,143.84
2,913.89
2,974.83
2,904.44
2,462.75
2,131.73
1,947.52
1,493.75
1,708.27
890.74
Current Investments
0.00
0.00
0.00
186.97
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,643.54
1,475.27
1,609.70
1,486.15
1,187.54
967.27
733.93
632.75
569.79
382.77
Sundry Debtors
1,024.84
1,046.41
807.13
348.60
864.75
488.92
526.34
338.82
350.48
361.17
Cash & Bank
126.57
82.27
69.43
105.84
80.75
205.62
89.92
159.60
450.83
26.83
Other Current Assets
348.89
55.32
51.65
78.67
329.71
469.92
597.33
362.58
337.17
119.98
Short Term Loans & Adv.
289.03
254.62
436.92
698.21
301.61
451.71
569.84
355.02
330.08
119.98
Net Current Assets
1,623.56
1,273.09
1,144.24
1,371.18
711.14
468.08
680.34
679.79
764.08
206.65
Total Assets
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
803.21
723.94
552.35
1,463.38
449.15
811.97
312.42
328.55
947.65
171.76
PBT
631.83
354.59
625.39
1,368.08
999.82
749.32
541.27
529.09
936.31
359.07
Adjustment
286.86
487.61
417.75
102.42
278.28
117.57
87.12
83.06
69.45
44.61
Changes in Working Capital
-95.63
-57.56
-367.36
238.30
-592.84
111.56
-180.85
-165.64
138.90
-162.50
Cash after chg. in Working capital
823.06
784.64
675.78
1,708.80
685.26
978.45
447.54
446.51
1,144.66
241.18
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-19.85
-60.70
-123.43
-245.42
-236.11
-166.48
-135.12
-117.96
-197.01
-69.42
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-320.61
-447.59
-371.97
-838.80
-731.63
-755.60
-884.38
-485.91
-306.80
-255.61
Net Fixed Assets
-340.94
994.77
-402.51
-1,303.18
-789.71
-638.70
-606.86
-121.60
-288.80
-200.26
Net Investments
2.59
-9.91
123.73
490.16
-326.86
-207.50
-195.85
-65.58
-4.13
0.00
Others
17.74
-1,432.45
-93.19
-25.78
384.94
90.60
-81.67
-298.73
-13.87
-55.35
Cash from Financing Activity
-437.87
-261.96
-217.35
-597.42
154.85
59.03
502.63
-128.88
-224.30
86.72
Net Cash Inflow / Outflow
44.73
14.39
-36.97
27.16
-127.63
115.40
-69.33
-286.24
416.55
2.86
Opening Cash & Equivalents
75.48
61.09
98.06
71.83
199.06
83.74
153.07
439.32
22.77
23.96
Closing Cash & Equivalent
120.21
75.48
61.09
98.06
71.84
199.07
83.74
153.08
439.32
26.83

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
245.14
222.36
266.47
257.80
170.79
144.24
117.78
100.92
84.74
46.93
ROA
9.93%
5.15%
7.34%
17.22%
14.64%
13.15%
12.25%
14.97%
33.76%
18.76%
ROE
13.40%
7.12%
10.11%
26.91%
26.97%
24.00%
20.42%
23.25%
58.03%
36.24%
ROCE
13.42%
7.44%
11.25%
26.28%
23.30%
22.66%
22.15%
28.87%
65.87%
37.54%
Fixed Asset Turnover
1.70
1.79
1.97
2.31
2.52
2.85
2.86
3.07
3.24
2.71
Receivable days
60.69
59.84
39.75
41.06
53.64
47.09
50.43
40.13
41.02
55.91
Inventory Days
91.38
99.60
106.49
90.48
85.38
78.91
79.67
70.01
54.91
61.11
Payable days
150.62
148.04
173.51
187.92
69.87
88.23
98.47
84.03
80.04
69.83
Cash Conversion Cycle
1.45
11.40
-27.27
-56.39
69.15
37.76
31.63
26.12
15.89
47.19
Total Debt/Equity
0.09
0.15
0.12
0.10
0.54
0.42
0.32
0.05
0.07
0.30
Interest Cover
12.24
8.07
36.27
86.40
37.81
41.70
160.20
102.16
173.43
95.30

News Update:


  • Alembic Pharmaceuticals receives USFDA’s final approval for Pantoprazole Sodium Injection
    1st Apr 2025, 16:30 PM

    Alembic has a cumulative total of 221 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals completes USFDA inspection for API-III Facility at Karakhadi
    22nd Mar 2025, 10:18 AM

    The inspection was conducted from March 17, 2025 to March 21, 2025

    Read More
  • Alembic Pharmaceuticals’ arm incorporates wholly-owned subsidiary in USA
    18th Mar 2025, 11:30 AM

    Alembic Global Holding SA will be making a remittance to Alembic LifeSciences Inc. towards subscription of 100% shareholding

    Read More
  • USFDA concludes inspection at Alembic Pharmaceuticals’ Vadodara facility
    10th Mar 2025, 10:07 AM

    The USFDA issued a form 483 with one procedural observation

    Read More
  • Alembic Pharma - Quarterly Results
    3rd Feb 2025, 14:37 PM

    Read More
  • Alembic Pharma gets USFDA’s approval for Brexpiprazole Tablets
    15th Jan 2025, 12:57 PM

    Alembic has a cumulative total of 220 ANDA approvals from USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.